Jose Manuel Otero - 18 Nov 2025 Form 4/A - Amendment Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Operating Officer
Signature
/s/ Carole Rosenberg, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
18 Nov 2025
Net transactions value
-$6,684
Form type
4/A - Amendment
Filing time
20 Feb 2026, 17:05:04 UTC
Date Of Original Report
20 Nov 2025
Previous filing
17 Oct 2025
Next filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Otero Jose Manuel Chief Operating Officer C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK /s/ Carole Rosenberg, Attorney-in-Fact 20 Feb 2026 0002024096

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Sale $6,684 -721 -1.1% $9.27 63,476 18 Nov 2025 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 20, 2025, the reporting person filed a Form 4 which inadvertently reported that a sale to cover tax obligations occurred on August 18, 2025. In fact, as reported in this amendment, the sale occurred on November 18, 2025.
F2 Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
F3 This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 Includes 47,733 RSUs.